Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study

Ida Sonni, Matthias Eiber, Wolfgang P. Fendler, Rejah M. Alano, Sitaram S. Vangala, Amar U. Kishan, Nicholas Nickols, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin and Jeremie Calais
Journal of Nuclear Medicine August 2020, 61 (8) 1153-1160; DOI: https://doi.org/10.2967/jnumed.119.237602
Ida Sonni
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Eiber
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
2Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang P. Fendler
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
3Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rejah M. Alano
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sitaram S. Vangala
4Department of Medicine Statistics Core, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amar U. Kishan
5Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
6Department of Urology, UCLA, Los Angeles, California
7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Nickols
5Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
6Department of Urology, UCLA, Los Angeles, California
7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Rettig
6Department of Urology, UCLA, Los Angeles, California
7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
8Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert E. Reiter
6Department of Urology, UCLA, Los Angeles, California
7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
8Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
8Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
8Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 8 1153-1160
DOI 
https://doi.org/10.2967/jnumed.119.237602
PubMed 
31924715

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication October 1, 2019
  • Accepted for publication December 17, 2019
  • Published online August 3, 2020.

Article Versions

  • previous version (January 10, 2020 - 04:59).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Ida Sonni1,
  2. Matthias Eiber1,2,
  3. Wolfgang P. Fendler1,3,
  4. Rejah M. Alano1,
  5. Sitaram S. Vangala4,
  6. Amar U. Kishan5–7,
  7. Nicholas Nickols5–7,
  8. Matthew B. Rettig6–8,
  9. Robert E. Reiter6–8,
  10. Johannes Czernin1,7,8 and
  11. Jeremie Calais1,7,8
  1. 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  2. 2Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
  3. 3Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  4. 4Department of Medicine Statistics Core, UCLA, Los Angeles, California
  5. 5Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  6. 6Department of Urology, UCLA, Los Angeles, California
  7. 7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
  8. 8Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  1. For correspondence or reprints contact: Ida Sonni, David Geffen School of Medicine, UCLA, 200 Medical Plaza, Suite B114, Los Angeles, CA 90095. E-mail: isonni{at}mednet.ucla.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 37 Citations
  • Google Scholar

Article usage

Article usage: January 2020 to May 2022

AbstractFullPdf
Jan 2020601091
Feb 2020263028
Mar 2020167029
Apr 2020172025
May 202096028
Jun 202093016
Jul 202054019
Aug 2020181826165
Sep 2020325843
Oct 2020139724
Nov 2020144532
Dec 2020140831
Jan 20211813345
Feb 2021678465
Mar 2021447458
Apr 20214710048
May 20213311138
Jun 2021298547
Jul 2021334844
Aug 2021226139
Sep 2021435055
Oct 2021569082
Nov 2021227376
Dec 2021279369
Jan 2022307271
Feb 2022268243
Mar 2022389270
Apr 20223614784
May 20222313879
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (8)
Journal of Nuclear Medicine
Vol. 61, Issue 8
August 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
Ida Sonni, Matthias Eiber, Wolfgang P. Fendler, Rejah M. Alano, Sitaram S. Vangala, Amar U. Kishan, Nicholas Nickols, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1153-1160; DOI: 10.2967/jnumed.119.237602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
Ida Sonni, Matthias Eiber, Wolfgang P. Fendler, Rejah M. Alano, Sitaram S. Vangala, Amar U. Kishan, Nicholas Nickols, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1153-1160; DOI: 10.2967/jnumed.119.237602
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study
  • Renal Cortical 68Ga-PSMA-11 PET and 99mTc-DMSA Images
  • Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
  • Google Scholar

More in this TOC Section

Theranostics

  • The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
  • A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
  • 89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice
Show more Theranostics

Clinical

  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Show more Clinical

Similar Articles

Keywords

  • PSMA PET
  • prostate cancer
  • Impact on management
  • staging
  • Restaging
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire